Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers Program.

Autor: Gwinn K; National Institute of Neurological Disorders & Stroke, National Institutes of Health, Bethesda, MD, USA., David KK; National Institute of Neurological Disorders & Stroke, National Institutes of Health, Bethesda, MD, USA., Swanson-Fischer C; National Institute of Neurological Disorders & Stroke, National Institutes of Health, Bethesda, MD, USA., Albin R; Neurology Service & GRECC, VAAAHS, UM Udall Center, University of Michigan, Ann Arbor, MI, USA., Hillaire-Clarke CS; National Institute on Aging, NIH, Bethesda, MD, USA., Sieber BA; National Institute of Neurological Disorders & Stroke, National Institutes of Health, Bethesda, MD, USA., Lungu C; National Institute of Neurological Disorders & Stroke, National Institutes of Health, Bethesda, MD, USA., Bowman FD; Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, NY, USA., Alcalay RN; Department of Neurology, Columbia University, New York, NY, USA., Babcock D; National Institute of Neurological Disorders & Stroke, National Institutes of Health, Bethesda, MD, USA., Dawson TM; Neuroregeneration & Stem Cell Programs, Institute for Cell Engineering, Solomon H Snyder Department of Neuroscience, Pharmacology & Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Dewey RB Jr; Department of Neurology & Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, TX, USA., Foroud T; Department of Medical & Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA., German D; Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA., Huang X; Department of Neurology, Penn State Hershey Medical Center, Hershey, PA, USA., Petyuk V; Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, USA., Potashkin JA; Department of Cellular & Molecular Pharmacology, Rosalind Franklin University of Medicine & Science, North Chicago, IL, USA., Saunders-Pullman R; Department of Neurology, Mount Sinai Beth Israel & Icahn School of Medicine at Mount Sinai, New York, NY, USA., Sutherland M; National Institute of Neurological Disorders & Stroke, National Institutes of Health, Bethesda, MD, USA., Walt DR; Department of Chemistry, Tufts University, Medford, MA, USA., West AB; Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA., Zhang J; Department of Pathology, University of Washington, Seattle, WA, USA., Chen-Plotkin A; Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA., Scherzer CR; Department of Neurology, Harvard Medical School, Brigham & Women's Hospital, Cambridge, MA, USA., Vaillancourt DE; Departments of Applied Physiology & Kinesiology, University of Florida, Gainesville, FL, USA., Rosenthal LS; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jazyk: angličtina
Zdroj: Biomarkers in medicine [Biomark Med] 2017 May; Vol. 11 (6), pp. 451-473. Date of Electronic Publication: 2017 Jun 23.
DOI: 10.2217/bmm-2016-0370
Abstrakt: Biomarkers for Parkinson's disease (PD) diagnosis, prognostication and clinical trial cohort selection are an urgent need. While many promising markers have been discovered through the National Institute of Neurological Disorders and Stroke Parkinson's Disease Biomarker Program (PDBP) and other mechanisms, no single PD marker or set of markers are ready for clinical use. Here we discuss the current state of biomarker discovery for platforms relevant to PDBP. We discuss the role of the PDBP in PD biomarker identification and present guidelines to facilitate their development. These guidelines include: harmonizing procedures for biofluid acquisition and clinical assessments, replication of the most promising biomarkers, support and encouragement of publications that report negative findings, longitudinal follow-up of current cohorts including the PDBP, testing of wearable technologies to capture readouts between study visits and development of recently diagnosed (de novo) cohorts to foster identification of the earliest markers of disease onset.
Databáze: MEDLINE